Abstract: PO1834
Effect of Hydroxychloroquine in Patients with IgA Nephropathy with Insufficient Responses to Immunosuppressive Therapy: A Retrospective Case-Control Study
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Trials - 1
October 22, 2020 | Location: On-Demand
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1203 Glomerular Diseases: Clinical, Outcomes, and Trials
Authors
- Tang, Chen, Peking University First Hospital, Beijing, Beijing, China
- Lv, Jicheng, Peking University First Hospital, Beijing, Beijing, China
- Shi, Sufang, Peking University First Hospital, Beijing, Beijing, China
- Chen, Yuqing, Peking University First Hospital, Beijing, Beijing, China
- Liu, Lijun, Peking University First Hospital, Beijing, Beijing, China
- Zhang, Hong, Peking University First Hospital, Beijing, Beijing, China
Background
Hydroxychloroquine, a well-known immunomodulator, has recently been used in IgA nephropathy (IgAN) due to its antiproteinuric effects. We aimed to verify the effect of HCQ in patients with IgAN whose proteinuria remained above 1 g/d after conventional immunosuppressive (IS) therapy
Methods
This was a retrospective case-control study. Twenty-six patients with IgAN who received HCQ and had insufficient responses to IS therapy (corticosteroid (CS) therapy with/without IS agents) were included. 26 matched historical controls who received conventional IS therapy were selected by propensity score matching. The clinical data from 6 months were compared
Results
Proteinuria at baseline was comparable between the “IS therapy plus HCQ” and “conventional IS therapy” groups (2.35 [interquartile range (IQR), 1.47, 2.98] vs. 2.35 [IQR, 1.54, 2.98] g/d, p=0.920). There was a significant reduction in proteinuria in patients with IgAN with HCQ treatment (2.35 [IQR, 1.47, 2.98] vs. 1.10 [IQR, 0.85, 1.61] g/d, p=0.002). The percent reduction in proteinuria at 6 months was similar between the two groups (-39.81% [-66.26, -12.37] vs. -31.99% [-67.08, -9.14], p = 0.968). The cumulative frequency of patients with a 50% reduction in proteinuria during the study was also comparable between the two groups (53.8% vs. 57.7%, p= 0.780). No serious adverse events were observed during the study
Conclusion
HCQ could further reduce proteinuria in patients with IgAN who had insufficient responses to conventional IS therapy
Proteinuria of enrolled patients
| IS therapy plus HCQ N=26 | Conventional IS therapy N=26 | P-value | |
| Proteinuria level before IS therapy (g/d) | 2.52(1.66,5.60) | 2.27(1.54,4.36) | 0.727 |
| Baseline Proteinuria (g/d) | 2.35(1.47,2.98) | 2.35(1.54,2.98) | 0.920 |
| Proteinuria at months 6（g/d） | 1.10(0.85,1.61) | 1.24(0.87,2.58) | 0.312 |
Proteinuria of patients during the follow-up. The dots represent the median value, the bars represent the 25th and 75th percentiles.Each Month's was compared with “Baseline” respectively. * p < 0.05; ** p < 0.01; *** p < 0.001